Excited about this today ✨ #ACNP2026

A study at NIDA/NIAAA by @rani-richardson.bsky.social and @mehdifarokhnia.bsky.social examined an inflammatory molecule LCN2 in people w/ AUD and alcohol-dependent rats. Time-based differences in LCN2 levels were observed in rats but not humans. Learn more here: www.tandfonline.com/doi/full/10....

New Chapter ✨

GLP-1s show promise in treating alcohol and drug addiction www.endocrine.org/news-and-adv... @endocrinesociety.bsky.social

GLP-1, ACNP, and Bahamas - not bad, not bad 😎 @acnporg.bsky.social #ACNP2026

Excited to talk GLP-1 and addiction this weekend! Thanks Endocrine Society for the invite ✨

NIDA IRP Featured Paper of the Month – July 2025 irp.nida.nih.gov/featured-pap...

#RSA2025 #RSA_ISBRA2025

Anecdotal reports and animal studies suggest that drugs like Ozempic reduce alcohol consumption. @mehdifarokhnia.bsky.social et al. now present a pharmacoepidemiologic study examining showing GLP-1RAs but not DPP-4 inhibitors reduce alcohol intake: buff.ly/BjP1kRB

🚨 Utilizing Blood Inflammatory Markers in Alcohol Studies: Considerations and Recommendations for Study Design, Sample Collection, and Data Analysis www.sciencedirect.com/science/arti...

Convergent findings across humans, including real world data, as well as studies in mice, and rats indicate that GLP-1RAs but not DPP-4Is reduce alcohol consumption and may be efficacious in treating alcohol use disorder @jclinical-invest.bsky.social www.jci.org/articles/vie...

Beyond weight loss and diabetes treatment, glucagon-like peptide-1 receptor (GLP-1R) agonists show promising clinical benefits for patients with eating disorders, neurodegenerative diseases, substance use disorders, and pain. (1/2)

The world is falling apart, but big paper accepted, so:

#NIH #NIHproud #SupportNIH